[A20-82] Ibalizumab (HIV infection) - Benefit assessment according to §35a Social Code Book V
Last updated 18.02.2021
Project no.:
A20-82
Commission:
Commission awarded on 01.09.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
| Adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen |
Result of dossier assessment:
| Appropriate comparator therapy not implemented; added benefit not proven |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.